Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 12 December, 2006

XTL Biopharm Ltd

XTL TO PRESENT AT THE NYSSA BIOTECH/SPECIALTY C...


 XTL BIOPHARMACEUTICALS TO PRESENT AT THE NYSSA 10TH ANNUAL BIOTECH/SPECIALTY  
                          PHARMA INDUSTRY CONFERENCE                           

NEW YORK, NEW YORK, December 12, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's
Chief Executive Officer, is scheduled to present at the NYSSA 10th Annual
Biotech/Specialty Pharma Industry Conference. Mr. Bentsur's presentation will
take place tomorrow, Wednesday, December 13, 2006, at 3:10 pm EST at the New
York Society of Security Analysts, 1177 Avenue of the Americas, 2nd Floor, in
New York City.

A live webcast of Mr. Bentsur's presentation will be available at http://
investor.shareholder.com/media/eventdetail.cfm?eventid=32512&CompanyID=XTLB&e=1
&mediaKey=77339C30E2C20AA2E62897E0416D0684. An archived version of the webcast
will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL
is also developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical trials in
patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule inhibitors.  XTL
also has an active in-licensing and acquisition program designed to identify
and acquire additional drug candidates. XTL is publicly traded on the NASDAQ,
London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).



Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960

 


                                                  

a d v e r t i s e m e n t